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ABSTRACT 
The objective of the current study was to develop a simple, accurate, precise and rapid RP-HPLC method with subsequently validate as per ICH 
guidelines for the determination of Alogliptin benzoate  and Metformin hydrochloride  using mobile phase [mixture of Phosphate buffer- pH-3.6 
and acetonitrile in the ratio of 65:35] as the solvent. The proposed method involves the measurement of Retention time at selected analytical 
wavelength. 235.0 nm was selected as the analytical wavelength. The retention time of ALO and MET was found to be 5.055 and 2.838 
respectively. The linearity of the proposed method was investigated in the range of 1-5 μg/ml (r = 0.9998) for ALO and 10-50μg/ml (r = 0.9999) 
for MET respectively. The method was statistically validated for its linearity, accuracy and precision. Both inter-day and intra-day variation was 
found to be showing less % RSD (Relative Standard Deviation) value indicating high grade of precision of the method.  
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INTRODUCTION: 
GLP-1 and glucose-dependent insulinotropic polypeptide 
(also known as gastric inhibitory peptide) belong to the 
incretin class of gastrointestinal hormones. Incretins 
stimulate a decrease in blood glucose levels by causing 
increased postprandial insulin release from the beta cells of 
the pancreas1. GLP-1 also suppresses glucagon secretion and 
exhibits other glucoregulatory actions after secretion in the 
gut.11 DPP-4 is an enzyme that rapidly degrades, and thereby 
inactivates, both GLP-1 and gastric inhibitory peptide. DPP-4 
inhibitors prolong the endogenous plasma levels and hence 
the activity of both of these key hormones.[2] Alogliptin, a 
potent and highly selective DPP-4 inhibitor, is the fourth 
DPP-4 inhibitor to be introduced in Canada, following the 
approval of sitagliptin, saxagliptin, and Alogliptin.  
 
Fig 1: Structure of Alogliptin 
Metformin is a biguanide oral hypoglycemic  primarily for 
treating type 2 diabetes mellitus (T2D). Evidence suggests 
that, in addition to improving glycemic control, metformin is 
associated with improved all-cause and cardiovascular 
mortality1 and decreased risk of some cancers (eg, breast 
cancer).2 Despite the potential benefits, since metformin was 
introduced in the United States in the mid-1990s, clinicians 
have been advised to exercise caution in prescribing the drug 
to individuals with certain comorbidities due to perceived 
risks of serious side effects, including LA. Lactic acidosis (LA) 
is defined as blood lactate concentration >45mg/dl 
(5.0mEq/L), decreased blood pH, and electrolyte 
disturbances with an increased anion gap 
 
 
Fig 2: Structure of Metformin 
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MATERIALS AND METHODS: 
Analytically pure sample of Alogliptin and Metformin with 
purities greater than 99% were obtained as gift samples. The 
tabulated information regarding the procurement of various 
samples are given below in table 1 and table 2 contains all 
the instrument list used for this work.
 
Table.No.1 List of chemicals and standards used 
Sr.no Chemical Manufacture name grade 
1 Water Merck HPLC grade 
2 Acetonitrile Merck HPLC grade 
3 Methanol Merck HPLC grade 
4 Ortho phosphoric acid Merck G.R 
5 Triethyl amine Merck G.R 
6 0. 22μ Nylon filter Advanced lab HPLC grade 
7 0.45μ filter paper Millipore HPLC grade 
8 Alogliptin And Metformin Gift samples from Ajanta Pharma 
(aurangabad, India) 
HPLC grade 
 
Table.No.2. List of instruments used. 
Weighing Balance PGB 100 
Ultra Sonicator WUC-4L 
UV-Spectrophotometer And Software UV2450 UV Probe v 2:3:3 
HPLC HPLC 3000 Series P-3000-M Reciprocating (Binary pump) 
UV-3000-M (UV-Visible Detecter) 
 
Selection of wavelength: 
10 mg of Alogliptin and Metformin was dissolved in mobile 
phase. The solution was scanned from 200-400 nm the 
spectrum was obtained. The overlay spectrum of alogliptin 
and Metformin was obtained and the isobestic point of 
Alogliptin And Metformin showed absorbance’s maxima at 
254 nm. The spectrums are shown in Fig. 3 
 
 
Fig.3. Spectrum showing overlapping spectrum of Alogliptin and Metformin 
 
The chromatographic method development for the 
simultaneous estimation of Alogliptin and Metformin were 
optimized by several trials for various parameters as 
different column, flow rate and mobile phase, finally the 
following chromatographic method was selected for the 
separation and quantification of Alogliptin and Metformin in 
API and pharmaceutical dosage form by RP-HPLC method. 
The separation of the drugs was achieved on Water X bridge 
C18 column (4.6×150mm) 5μ particle size). The mobile 
phase consists of a mixture of Methanol: Acetonitrile pH 3.0 
(130: 870 % v/v) at a flow rate of 1.0 ml/minute and the 
volume injected was 10 μl for every injection .the detection 
wavelength was set at 240 nm. 
Preparation of Buffer solution: (Mobile phase A). 
Add 0.25 g of Sodium 1-octane Sulfonate monohydrate in 
1000 mL of water, mix and filterthe solution through 0.45µ 
Nylon membrane disc filter, to this add 2.0 mL of 
Triethylaminemix and adjust the pH 3.0 ± 0.1 with Ortho-
phosphoric acid Mix and degas 
1. Preparation of Mobile Phase B: 
Mix Acetonitrile and Methanol in the proportion of 
870:130 v/v respectively and use as mobile phase B. 
2. Preparation of Mobile Phase: 
Prepare the mixture of Mobile phase A: Mobile Phase B 
in the ratio of 85:15 v/v respectively. 
3. Preparation of Diluent: 
Prepare mixture of Water and Acetonitrile in the ratio 
85:15 v/v respectively, mix and degas. 
 
 
Andhale et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2019; 9(4):504-509 
  
ISSN: 2250-1177                                                                                  [506]                                                                                 CODEN (USA): JDDTAO 
4. Preparation of Standard stock solution: 
Alogliptin Stock. 
Weigh accurately about 25 mg of Alogliptin standard and 
transfer into  50 mL volumetric flask. Add about 30 mL of 
diluent, sonicate to dissolve and make up to volume with 
diluent and mix. 
Metformin HCl Stock. 
Weigh accurately about 50 mg of Metformin HCl standard 
and transfer into 100 mL volumetric flask. Add about 70 mL 
of diluent, sonicate to dissolve and make up to volume with 
diluent and mix. 
5. Preparation of Standard solution: 
 Further transfer 10 mL Metformin HCl Stock Solution and 
20 mL ofAlogliptin  Stock Solution into 50 mL volumetric 
flask and dilute up to the mark with diluent and mix.  
6. Preparation of Sample Stock solution:  
 Weigh and transfer 10 tablets into 1000 mL volumetric 
flask. Add about 700 mL of diluent, sonicate for 30 minutes 
with intermittent shaking. Allow it to cool to room 
temperature and make up to volume with diluent and mix. 
Let the solution stand for 5 minutes.  
 Filter the sample solution through 0.45µ Nylon membrane 
syringe filter. Discard first 3 mL of filtrate. 
RESULTS AND DISCUSSION 
Method Development. 
A Reverse phase HPLC method was developed keeping in 
mind the system suitability parameters i.e. resolution factor 
(Rf) between peaks, tailing factor (T), number of theoretical 
plates (N), runtime and the cost effectiveness. The optimized 
method developed resulted in the elution of Alogliptin at 6.2 
min and Metformin at 2.6 min. 
Figure 4 represents chromatograms of mixture of standard 
solutions. The total run time is 25 minutes with all system 
suitability parameters as ideal for the mixture of standard 
solutions.
 
 
Fig 4: Typical chromatogram of the mixture of the standard  sample. 
 
System‐suitability tests are an integral part of method 
development and are used to ensure adequate performance 
of the chromatographic system. Retention time (Rt), number 
of theoretical plates (N), peak resolution (Rs) and peak 
Tailing factor (T) were evaluated for six replicate injections 
of the standards at working concentration. The results given 
in Table 3 were within acceptable limits. 
 
Table 3: System suitability studies results. 
PARAMETERS* REQUIRED LIMITS Alogliptin Metformin 
Retention time (min) % RSD < 1% 6.2 2.6 
Number Of Theoretical plates (N) Not less Than 2000 4423 6049 
Tailing factor (T) Not More Than 2 1.3 1.2 
 
Method validation 
Validation of the analytical method is the process that 
establishes by laboratory studies in which the performance 
characteristics of the method meet the requirements for the 
intended analytical application. The RP-HPLC method 
developed was validated according to International 
Conference on Harmonization10 guidelines for validation of 
analytical procedures. The method was alidate for the 
parameters in terms of system suitability, selectivity, 
linearity, accuracy, precision, ruggedness, robustness, limit 
of detection(LOD) and limit of quantitation(LOQ). 
Specificity. 
The system suitability for specificity was carried out to 
determine whether there is any interference of any 
impurities in retention time of analytical peak. The study 
was performed by injecting blank. The chromatograms are 
shown in Fig.No.5.7.
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Fig.5.7 Chromatogram showing blank (mobile phase preparation) 
 
Fig.6. Chromatogram showing standard injection 
Linearity. 
The linearity study was performed for the concentration of 
10 ppm to 50 ppm Alogliptin and 20 ppm to 100 ppm 
Metformin level. Each level was injected into 
chromatographic system. The area of each level was used for 
calculation of correlation coefficient. The results 
aretabulated in Table.4-5. Calibration graph for Alogliptin 
and Metformin are shown in Fig.No.8 &Fig 9. 
 
Table 4. Linearity Results for Alogliptin 
Sr.No Linearity level Concentration Area 
1 1 50ppm 703249 
2 2 80ppm 1119712 
3 3 90ppm 1263844 
4 4 100ppm 1399228 
5 5 150ppm 2081515 
  Correlation Coefficient 1.000 
 
Table 5. Linearity Results for Metformin 
Sr.no Linearity level Concentration Area 
1 1 50ppm 1639365 
2 2 80ppm 2610330 
3 3 90ppm 2955233 
4 4 100ppm 3268898 
5 5 150ppm 4865242 
  Correlation Coefficient 1.000 
 
The linearity study was performed for concentration range 
of 50μg -150μg Alogliptin and 50μg - 150 μg metformin and 
the correlation coefficient was found to be 1.000 and 
1.000.(NLT 0.999)respectively. 
 
Accuracy: 
The accuracy study was performed for 50%, 100% and 150 
% for Alogliptin and Metformin. Each levelwas injected in 
triplicate into chromatographic system. T he area of each 
level was used for calculation of % recovery. The results are 
tabulated in Table.No.6-7. 
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Table: 6. Accuracy results for Alogliptin. 
%Concentration (at specification level) Average area % Recovery Mean recovery 
50% 1411902 98.4  
98.8 100% 1400900 98.9 
150% 1404583 99.2 
 
Table.7. Accuracy results for Metformin. 
%Concentration (at specification level) Average area % Recovery Mean recovery 
50% 3438212 102.2  
100.5 100% 3409956 100.3 
150% 3408213 100.4 
 
The accuracy study was performed for % recovery of 
Alogliptin and Metformin. The % recovery was found to be 
98.8 % and 100.5% respectively (NLT 98% and NMT 
102%). 
Precision. 
 1.system precision 
 2.Method precision 
1.0 system precision. 
Single injection of Blank (Diluent) and six replicate 
injections of standard solution were injected on the 
system. The data obtained is summarized in Table 9.
 
Table ` 9: System precision 
 For Alogliptin For Metformin HCl 
Symmetry factor 1.3 1.2 
Theoretical plates 4423 6049 
S. No. Area Area 
1 1398462 3408366 
2 1399489 3418137 
3 1401540 3407958 
4 1399820 3415686 
5 1401309 3423660 
6 1400876 3416303 
Mean 1400249.333 3415018.333 
%RSD 0.09 0.18 
 
6.5.2 Method Precision: 
Six independent sample preparations were prepared and injected in duplicate on the HPLC. The data obtained is summarized in 
Table 10 and 11, 12. 
For Alogliptin 
Response 
Sample no 1 2 3 % Assay 
1 1323512 1324023 1323767.5 95.3 
2 1336783 1336081 1336432 96.2 
3 1319381 1325423 1322402 95.2 
4 1364166 1363980 1364073 98.2 
5 1363272 1359189 1361230.5 98.0 
6 1336870 1335388 1336129 96.2 
   mean 96.5 
   %RSD 1.35 
     
 
For Metformin. 
Sample no 1 2 3 % Assay 
1 3402226 3401364 3401795 98.5 
2 3399658 3398478 3399068 98.4 
3 3406175 3419096 3412635.5 98.8 
4 3404064 3439805 3421934.5 99.0 
5 3407303 3416774 3412038.5 98.8 
6 3376031 3397298 3386664.5 98.0 
   mean 98.6 
   % RSD 0.37 
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Intermediate precision/Ruggedness. 
Same procedure of method precision is followed by another 
Analyst by using same lot of Alogliptin and Metformin HCl 
Tablets on different instrument  different column and on 
different day. The data obtained from Analyst-II are 
summarized in Table 13. 
 
Table 13: System suitability 
 For Alogliptin For Metformin 
The symmetry factor for 
Alogliptin peak 
1.4 1.2 
The EP theoretical plates for 
Alogliptin peak 
6459 4281 
Sr.no Area Area 
1 1499519 3684107 
2 1494289 3670036 
3 1498845 3685519 
4 1503497 3698331 
5 1505602 3706061 
6 1506060 3709982 
Mean 1501302 3692339.333 
% RSD 0.30 0.41 
 
CONCLUSION: 
The data shows that % assay difference of unfiltered 
standard solution and filtered standard solution with 
different filters is within the acceptance criteria. Hence 
Nylon filter, PVDF filters are suitable for standard solution. 
The data shows that % assay between centrifuged sample 
solution and filtered sample solution with 0.45µ PVDF filter, 
Nylon filter is within the acceptance criteria. Hence all tested 
filters except Teflon+Glass filter are suitable for sample 
solution filtration. 
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